Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

By R. Christensen, P. K. Kristensen, E. Bartels, H. Bliddal, A. Astrup. The Lancet, 2007

1,016 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Neurobiological Interactions Between Stress and the Endocannabinoid System (2016, positive): “…studies and meta-analyses demonstrated that indices of anxiety and depression significantly increased following sustained rimonabant treatment (Christensen et al, 2007; Hill and Gorzalka, 2009a; Mitchell and Morris, 2007; Topol et al, 2010); in fact, there was even a published case report of…”
The endocannabinoid system and the brain. (2013, background): “D ow nl oa de d fr om w w w .a nn ua lr ev ie w s. or g by K A R O L IN SK A I N ST IT U T E T U N IV E R SI T Y L IB R A R Y o n 08 /0 8/ 12 .”
An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity (2016, background): “However the drug was withdrawn from the market due to severe side effects that led to increased risk of anxiety, depression, and suicide [108].”